Evidence map›Paper›PMID 36983764›Full record

ArticleLife (Basel, Switzerland)2023

Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Derived from These Tumors.

Fiona O'Neill, Taylor-Jade Allen-Coyle, Sandra Roche, Justine Meiller, Neil T Conlon, Niall Swan, Robert M Straubinger, Justin Geoghegan, Ninfa L Straubinger, Kevin Conlon and 8 more

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Fiona O'NeillNational Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.
Taylor-Jade Allen-CoyleNational Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.
Sandra RocheNational Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.ORCID 0000-0002-4363-4607
Justine MeillerNational Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.
Neil T ConlonNational Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.ORCID 0000-0001-5921-7114
Niall SwanSt. Vincent's University Hospital, D04 T6F4 Dublin, Ireland.
Robert M StraubingerDepartment of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, NY 14214, USA.ORCID 0000-0003-0870-9236
Justin GeogheganSt. Vincent's University Hospital, D04 T6F4 Dublin, Ireland.
Ninfa L StraubingerDepartment of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, NY 14214, USA.
Kevin ConlonSt. Vincent's University Hospital, D04 T6F4 Dublin, Ireland.
Ray McDermottSt. Vincent's University Hospital, D04 T6F4 Dublin, Ireland.ORCID 0000-0002-8952-4315
Finbarr O'SullivanNational Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.ORCID 0000-0003-1238-5721
Michael HenryNational Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.
Paula MeleadyNational Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.
Gerard McVeySt. Luke's Hospital, Rathgar, D06 HH36 Dublin, Ireland.
Robert O'ConnorNational Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.ORCID 0000-0003-4426-2507
Michael MoriartyNational Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.
Martin ClynesNational Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.ORCID 0000-0002-3093-8185
Dublin City University · IEScience Foundation Ireland · IESt. Vincent's University Hospital · IESt. Luke's Hospital · IEUniversity at Buffalo, State University of New York · US

Funding

Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortiumR01CA198096 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI CLYNES, MARTIN, MA, WEN WEE · 2015 to 2019
$2.2M
NCI NIH HHS R01 CA198096Pancreatic Cancer Research Fund N/aScience Foundation Ireland 12/RC/2275_P2St Luke's Inititute for Cancer Research Collaborative Research Programme on Radiation Biology and Proteomics of Pancreatic CancerUS-Ireland R&D Partnership SFI SFI/14/US/B2997
6 · The paper itself

Abstract

Herein, we describe the global comparison of miRNAs in human pancreatic cancer tumors, adjacent normal tissue, and matched patient-derived xenograft models using microarray screening. RNA was extracted from seven tumor, five adjacent normal, and eight FI PDX tumor samples and analyzed by Affymetrix GeneChip miRNA 4.0 array. A transcriptome analysis console (TAC) was used to generate comparative lists of up- and downregulated miRNAs for the comparisons, tumor vs. normal and F1 PDX vs. tumor. Particular attention was paid to miRNAs that were changed in the same direction in both comparisons. We identified the involvement in pancreatic tumor tissue of several miRNAs, including miR4534, miR3154, and miR4742, not previously highlighted as being involved in this type of cancer. Investigation in the parallel mRNA and protein lists from the same samples allowed the elimination of proteins where altered expression correlated with corresponding mRNA levels and was thus less likely to be miRNA regulated. Using the remaining differential expression protein lists for proteins predicted to be targeted for differentially expressed miRNA on our list, we were able to tentatively ascribe specific protein changes to individual miRNA. Particularly interesting target proteins for miRs 615-3p, 2467-3p, 4742-5p, 509-5p, and 605-3p were identified. Prominent among the protein targets are enzymes involved in aldehyde metabolism and membrane transport and trafficking. These results may help to uncover vulnerabilities that could enable novel approaches to treating pancreatic cancer.

Indexed as

miRNApancreatic cancerPDXtumour

Identifiers

PMID36983764
PMCPMC10057657
OpenAlexW4321496156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.